Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated human epidermal growth factor receptor 2 (HER2/neu) positive metastatic breast cancer to assess progression-free survival.

Trial Profile

Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated human epidermal growth factor receptor 2 (HER2/neu) positive metastatic breast cancer to assess progression-free survival.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jun 2016

At a glance

  • Drugs Lapatinib (Primary) ; Vinorelbine (Primary)
  • Indications Advanced breast cancer; Breast cancer
  • Focus Therapeutic Use
  • Acronyms TyN
  • Most Recent Events

    • 16 May 2016 Status changed from discontinued to completed.
    • 11 Jun 2015 Status changed from active, no longer recruiting to discontinued as per Australian New Zealand Clinical Trials Registry record.
    • 11 May 2012 Planned number of patients changed from 70 to 20 as reported by Australian New Zealand Clinical Trials Registry.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top